News
ARMP
2.500
-1.19%
-0.030
Weekly Report: what happened at ARMP last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at ARMP last week (0408-0412)?
Weekly Report · 04/15 10:02
Weekly Report: what happened at ARMP last week (0401-0405)?
Weekly Report · 04/08 10:05
Weekly Report: what happened at ARMP last week (0325-0329)?
Weekly Report · 04/01 10:03
Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Development
TipRanks · 03/25 10:46
Weekly Report: what happened at ARMP last week (0318-0322)?
Weekly Report · 03/25 10:05
Armata Pharmaceuticals Under Pressure: Navigating the Risks as Cost-Cutting Measures Threaten Revenue
TipRanks · 03/23 06:00
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/22 15:09
Armata Pharmaceuticals Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/22 15:09
HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Benzinga · 03/22 14:58
Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth
TipRanks · 03/22 10:17
ARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
Armata Pharmaceuticals reported results for the fourth quarter of 2023. The company reported earnings per share of -55 cents. Armata pharmaceuticals reported revenue of $1.53 million. This was 77.67% better than the analyst estimate for revenue in the quarter.
Investorplace · 03/22 02:53
Armata Pharmaceuticals reports Q4 results
Armata Pharmaceuticals, Inc. Reports Q4 results. Loss from operations for the three months ended December 31, 2023 was $9.6 million. The company recognized grant revenue of approximately $1.5 million. Armata held approximately $13.5million of unrestricted cash and cash equivalents.
Seeking Alpha · 03/21 21:19
*Armata Pharmaceuticals 4Q R&D Expenses $7.9M >ARMP
Dow Jones · 03/21 20:12
*Armata Pharmaceuticals 4Q Grant Rev $1.5M >ARMP
Dow Jones · 03/21 20:12
Press Release: Armata Pharmaceuticals Announces -2-
Relating to Armata and its business can be found under the caption "Risk Factors" in Armata's filings and reports with the SEC. Armata expressly disclaims any obligation to update or revise any forward-looking statements. The company's assets include cash and cash equivalents and other assets.
Dow Jones · 03/21 20:05
*Armata Pharmaceuticals 4Q Loss/Shr 55c >ARMP
Dow Jones · 03/21 20:05
Press Release: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. Announced financial results for its fourth quarter and full-year ended December 31, 2023. The biotechnology company is focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Armata expects to complete construction of its advanced facility in the first half of 2024.
Dow Jones · 03/21 20:05
Armata Pharmctcl: Statement of changes in beneficial ownership of securities
Press release · 03/19 02:09
More
Webull provides a variety of real-time ARMP stock news. You can receive the latest news about Armata Pharmctcl through multiple platforms. This information may help you make smarter investment decisions.
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.